Table 2.

Main survival analyses with complete data for the primary and the secondary outcomes according to first-line treatment, immune checkpoint inhibitors vs. chemotherapy (reference) (N = 4277), ESME AMLC Database, France 2015–2019.

	Overall survival			Progression-free survival
	HR	95% CI	P-value	HR	95% CI	P-value
Model 1a: immune checkpoint inhibitors vs chemotherapy (ref)
PS 0-1c
Before 3 months	1.00	0.61–1.64	0.985	1.02	0.76–1.37	0.893
After 3 months	0.59	0.42–0.83	0.003	0.46	0.34–0.61	< 0.001
PS 2–3-4c
Before 3 months	2.28	1.17–4.47	0.016	1.65	1.02–2.67	0.040
After 3 months	0.85	0.36–2.04	0.719	0.84	0.34–2.13	0.720
Model 2b: immune checkpoint inhibitors vs chemotherapy (ref)
PS 0-1c
Before 3 months	0.98	0.60–1.62	0.944	0.98	0.73–1.31	0.893
After 3 months	0.58	0.41–0.83	0.002	0.44	0.33–0.59	< 0.001
PS 2–3-4c
Before 3 months	2.25	1.15–4.39	0.018	1.63	1.01–2.63	0.047
After 3 months	0.84	0.35–2.01	0.689	0.83	0.35–2.01	0.692

Significant results are in bold.

Ref reference, 95% CI confidence interval of 95%.

^aModel 1: adjustment on gender, age, performance status, metastases localization, center, comorbidities (kidney failure, cardiovascular disease, history of other cancer), histology, delay to treatment initiation.

^bModel 2: adjustment on gender, age, performance status, metastases localization, center, comorbidities (kidney failure, cardiovascular disease, history of other cancer), histology, year of initiation.

^cp-value for interaction treatment with performance status < 0.001.